ARTICLE | Deals
Plus: Iaso gets full rights to Fucaso from Innovent, and updates from Genexine, EPD, Pentixapharm and Glycotope
By Gunjan Ohri, Data Content Analyst
July 8, 2024 11:23 PM UTC
At least five deals were announced in the past seven days, including Eli Lilly’s $3.2 billion acquisition of Morphic, and GSK gaining full rights of mRNA vaccines from CureVac.
Eli Lilly and Co. (NYSE:LLY) acquired Morphic Holding Inc. (NASDAQ:MORF), an oral integrin therapies company for $57 per share, a 79% premium over Friday’s close, valuing the deal at nearly $3.2 billion. Morphic’s lead program, MORF-057, is in Phase II studies for ulcerative colitis and Crohn’s disease. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652912/deals-report-lilly-acquires-morphic-gsk-gets-full-rights-for-mrna-vaccines-from-curevac